Kozak & Associates’s Vivos Therapeutics VVOS Stock Holding History

Kozak & Associates’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24	Hold	49	–	–	﹤0.01%	432
2026 Q1	$60	Hold	49	–	–	﹤0.01%	430
2025 Q4	$101	Hold	49	–	–	﹤0.01%	413
2025 Q3	$117	Hold	49	–	–	﹤0.01%	432
2025 Q2	$294	Hold	49	–	–	﹤0.01%	391
2025 Q1	$110	Hold	49	–	–	﹤0.01%	413
2024 Q4	$214	Hold	49	–	–	﹤0.01%	395
2024 Q3	$124	Hold	49	–	–	﹤0.01%	375
2024 Q2	$118	Hold	49	–	–	﹤0.01%	374
2024 Q1	$111	Hold	49	–	–	﹤0.01%	377
2023 Q4	$351	Buy	49 +1	+2%	+$9	﹤0.01%	347
2023 Q3	$335	Hold	48	–	–	﹤0.01%	370
2023 Q2	$602	Hold	48	–	–	﹤0.01%	339
2023 Q1	$411	Hold	48	–	–	﹤0.01%	333
2022 Q4	$0	Hold	48	–	–	﹤0.01%	342
2022 Q3	$1K	Hold	48	–	–	﹤0.01%	321
2022 Q2	$2K	Hold	48	–	–	﹤0.01%	347
2022 Q1	$4K	Hold	48	–	–	﹤0.01%	329
2021 Q4	$4K	Hold	48	–	–	﹤0.01%	329
2021 Q3	$5K	Buy	+48	New	+$5.04K	﹤0.01%	281

Other funds holding VVOS

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Kozak & Associates's VVOS Position: Q2 2026 in Review

Kozak & Associates held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 49 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #432.

Kozak & Associates first reported a position in VVOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $5K in Q3 2021. 4 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Kozak & Associates held 49 shares of Vivos Therapeutics worth $24 as of Q2 2026.
Kozak & Associates left its Vivos Therapeutics share count unchanged in Q2 2026.
Vivos Therapeutics made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #432 holding.
Kozak & Associates first reported a position in Vivos Therapeutics in Q3 2021 and has held it in 20 quarters since.
Kozak & Associates's Vivos Therapeutics position peaked at $5K in Q3 2021.
4 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.